XXXX : abnormal exogenous lipid metabolism evidenced by the @entity904 test.

@entity6247 @entity154 @entity1 @entity8444 @entity753 @entity1007 @entity3413 @entity407 @entity1674 @entity95 @entity904 @entity4741 @entity5522 @entity412 @entity209 @entity165
@entity753 is a @entity209 associated with high LDL levels attributed to a @entity154 in LDL receptor activity. We have previously shown that @entity5522 of WHHL @entity95 , considered to be a model for heritable @entity1007 , was at least partly of exogenous origin. We have though studied @entity6247 (RP) levels 12 h after a standardized mixed meal as a simple test to detect abnormalities of intestinal-derived lipoprotein clearance in 22 @entity753 @entity1 with @entity4741 (13 of them treated by @entity3413 , an @entity8444 inhibitor, and 9 not treated), as compared to a control group (n = 12). Total and LDL @entity165 , plasma @entity412 and apo B levels were significantly higher in @entity1 when compared to controls. Mean RP levels appeared higher in @entity753 @entity1 , when compared to controls, with 6 among 22 @entity1 showing clearly high @entity904 levels and 4 borderline values, whereas high @entity412 levels (> 2 g/l) were detected in only 1 @entity1 . No @entity1 within the group with high @entity904 levels showed an apo E2/E2 phenotype. @entity904 levels correlated with plasma @entity1674 in the whole group of subjects (r = 0.50, p < 0.05). No difference was observed in @entity904 distribution between treated and untreated @entity753 @entity1 . Our results indicate that the clearance of RP-labeled intestinal lipoproteins is delayed in some xanthomatous @entity753 @entity1 as compared with that of controls. These findings suggest that @entity753 may be heterogenous concerning physiopathological mechanisms inducing @entity407 .
